Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Incidence, diagnosis and prognosis of cardiac amyloidosis.

Lee MH, Lee SP, Kim YJ, Sohn DW.

Korean Circ J. 2013 Nov;43(11):752-60. doi: 10.4070/kcj.2013.43.11.752.

2.

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, Zugck C, Galuschky C, Giannitsis E, Hegenbart U, Ho AD, Katus HA, Schonland SO, Hardt SE.

J Am Coll Cardiol. 2012 Sep 18;60(12):1067-76. doi: 10.1016/j.jacc.2012.04.043.

3.

Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring.

Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM.

Am J Cardiol. 2009 Oct 1;104(7):990-4. doi: 10.1016/j.amjcard.2009.05.040.

PMID:
19766769
4.

Focus on cardiac amyloidosis: a single-center experience with a long-term follow-up.

Finocchiaro G, Pinamonti B, Merlo M, Giannini F, Barbati G, Pivetta A, Santarossa E, Doimo S, DePellegrin A, Bussani R, Sinagra G.

J Cardiovasc Med (Hagerstown). 2013 Apr;14(4):281-8. doi: 10.2459/JCM.0b013e3283536534.

PMID:
22609869
5.

Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis.

Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, Landau H, Liu JE.

Am J Cardiol. 2012 Oct 15;110(8):1180-4. doi: 10.1016/j.amjcard.2012.05.061.

PMID:
22770934
6.

Presentation and outcome of patients with systemic amyloidosis undergoing dialysis.

Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F.

Clin J Am Soc Nephrol. 2008 Mar;3(2):375-81. doi: 10.2215/CJN.02470607.

7.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, Lavatelli F, Marena C, Merlini G.

JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):891-4. doi: 10.1177/0148607113501328.

PMID:
24072737
8.

Impact of regional left ventricular function on outcome for patients with AL amyloidosis.

Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Störk S, Beer M, Gaudron PD, Morbach C, Knop S, Geissinger E, Ertl G, Bijnens B, Weidemann F.

PLoS One. 2013;8(3):e56923. doi: 10.1371/journal.pone.0056923.

9.

Diagnostic and prognostic value of subcutaneous tissue biopsy in patients with cardiac amyloidosis.

Takashio S, Izumiya Y, Jinnin M, Yamamuro M, Kojima S, Ihn H, Ogawa H.

Am J Cardiol. 2012 Nov 15;110(10):1507-11. doi: 10.1016/j.amjcard.2012.06.059.

PMID:
22863178
10.

Al amyloidosis.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A; Centre national de référence pour l’amylose AL et les autres maladies par dépôts d’immunoglobulines monoclonales..

Orphanet J Rare Dis. 2012 Aug 21;7:54. doi: 10.1186/1750-1172-7-54. Review.

11.

Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.

Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G.

Clin Chem. 2009 Mar;55(3):499-504. doi: 10.1373/clinchem.2008.117143.

12.

Comparison of usefulness between exercise capacity and echocardiographic indexes of left ventricular function in cardiac amyloidosis.

Trikas A, Rallidis L, Hawkins P, Oakley CM, Nihoyannopoulos P.

Am J Cardiol. 1999 Nov 1;84(9):1049-54.

PMID:
10569662
13.

Prognosis of patients with primary systemic amyloidosis who present with dominant neuropathy.

Rajkumar SV, Gertz MA, Kyle RA.

Am J Med. 1998 Mar;104(3):232-7.

PMID:
9552085
14.

MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis.

Hosch W, Bock M, Libicher M, Ley S, Hegenbart U, Dengler TJ, Katus HA, Kauczor HU, Kauffmann GW, Kristen AV.

Invest Radiol. 2007 Sep;42(9):636-42.

PMID:
17700279
15.

Amyloidosis and cardiac involvement.

Cacoub P, Axler O, De Zuttere D, Hausfater P, Amoura Z, Walter S, Wechsler B, Godeau P, Piette JC.

Ann Med Interne (Paris). 2000 Dec;151(8):611-7.

PMID:
11173703
16.

Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.

Ahmari SA, Bunch TJ, Chandra A, Chandra V, Ujino K, Daly RC, Kushwaha SS, Edwards BS, Maalouf YF, Seward JB, McGregor CG, Chandrasekaran K.

J Heart Lung Transplant. 2006 Jan;25(1):53-60.

PMID:
16399531
17.

Primary systemic amyloidosis--a diagnostic primer.

Gertz MA, Kyle RA.

Mayo Clin Proc. 1989 Dec;64(12):1505-19. Review.

PMID:
2513459
18.

High-sensitive troponin T and I are related to invasive hemodynamic data and mortality in patients with left-ventricular dysfunction and precapillary pulmonary hypertension.

Eggers KM, Nygren M, Venge P, Jernberg T, Wikström BG.

Clin Chim Acta. 2011 Aug 17;412(17-18):1582-8. doi: 10.1016/j.cca.2011.05.007.

PMID:
21605552
19.

Primary systemic amyloidosis.

Comenzo RL.

Curr Treat Options Oncol. 2000 Apr;1(1):83-9. Review.

PMID:
12057064
20.

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G.

Circulation. 2003 May 20;107(19):2440-5.

Items per page

Supplemental Content

Support Center